Provectus Biopharmaceuticals Announces Presentation of Preclinical PV-10 Vaccine Adjuvant Data at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
06 nov. 2023 08h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that preclinical data from ongoing research on the potential use of investigational cancer immunotherapy...
Evaxion Announces Encouraging Initial Phase 2 Clinical Data on Its Personalized Cancer Vaccine EVX-01
31 oct. 2023 11h15 HE
|
Evaxion Biotech
Initial EVX-01 Phase 2 data confirms the strong Phase 1 results After undergoing EVX-01 treatment, a significant and continuous tumor reduction was observed in a metastatic melanoma patient with...
Cancer Vaccine Market Anticipates 11.8% CAGR Fueled by Government Funding and Research Initiatives - Marketresearch.biz Study
23 oct. 2023 06h50 HE
|
MarketResearch.biz
New York, Oct. 23, 2023 (GLOBE NEWSWIRE) -- The cancer vaccine market is expected to witness growth with an estimated increase from US$ 6.8 Billion in 2022 to around US$ 20.2 Billion by the year...
[Latest] Global Cancer Vaccine Market Size Envisioned at USD 18.03 Billion by 2030, Increasing a CAGR of 11.6% | Healthcare Revolution
11 sept. 2023 07h42 HE
|
Zion Market Research
NEW YORK, United States, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Zion Market Research has published a new research report titled “Cancer Vaccine Market By Type (Preventive Cancer Vaccines, And...
Provectus Biopharmaceuticals Announces Acceptance of PV-10 Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
07 août 2023 07h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that preclinical data from ongoing research on investigational cancer immunotherapy PV-10 (rose bengal...
Evaxion unveils proprietary genetic adjuvant technology to boost the effect of DNA and mRNA vaccines
25 mai 2023 17h00 HE
|
Evaxion Biotech
Evaxion developed a genetic adjuvant technology that boosts the immune responses of viral, bacterial and cancer vaccinesPreclinically validated for both DNA and mRNA vaccines, and ready for clinical...
Evaxion Announces Increased Focus and Fast-Tracking of its New AI Discovery to Patients
28 mars 2023 07h46 HE
|
Evaxion Biotech
New AI discovery de-risking the pipeline through faster validation and has potential to enter clinical Phase 1/2a in Q4 2023Phase 2b clinical trial reduced in size and expected to reach interim data...
Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR)
14 mars 2023 16h30 HE
|
Evaxion Biotech
COPENHAGEN, Denmark, March 14, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
Sunshine Biopharma Signs Research Agreement With the Jewish General Hospital to Advance the Development of Adva-27a Anticancer Compound
10 févr. 2023 07h35 HE
|
Sunshine Biopharma Inc.
MONTREAL, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas...
Cell BioEngines Enters into an Exclusive Worldwide Agreement to Develop and Commercialize Potent Immune Cell States to Cure Cancer
25 janv. 2023 21h15 HE
|
Cell BioEngines, Inc.
BOSTON and NEW YORK, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Cell BioEngines Inc. (the “Company”), a cell and gene therapy company focused on developing an allogenic cell-based product for solid tumors,...